Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126664531 | 12666453 | 1 | I | 20160812 | 20160819 | 20160819 | PER | PHEH2016US020446 | NOVARTIS | 0.00 | F | Y | 0.00000 | 20160819 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126664531 | 12666453 | 1 | PS | SANDOSTATIN | OCTREOTIDE ACETATE | 1 | Unknown | 150 UG, QD (0.75 ML) | U | 19667 | 150 | UG | QD | ||||||
| 126664531 | 12666453 | 2 | SS | OCTREOTIDE. | OCTREOTIDE | 1 | Unknown | U | 19667 | ||||||||||
| 126664531 | 12666453 | 3 | C | RALOXIFENE. | RALOXIFENE | 1 | Unknown | U | 0 | ||||||||||
| 126664531 | 12666453 | 4 | SS | VITAMINS NOS | VITAMINS | 1 | Unknown | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126664531 | 12666453 | 1 | Product used for unknown indication |
| 126664531 | 12666453 | 2 | Product used for unknown indication |
| 126664531 | 12666453 | 3 | Scoliosis |
| 126664531 | 12666453 | 4 | Product used for unknown indication |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126664531 | 12666453 | Drug ineffective | |
| 126664531 | 12666453 | Injection site pain | |
| 126664531 | 12666453 | Thyroid mass |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |